V

Varian

Tech-enabled radiation oncology hardware and software

Business Development Director - Molecular Imaging, National Imaging Centers

Full-Time
$189.9k - $261.2k+ Commission
Expert
Remote in USA
RemoteApproximately 50% travel to support strategic customers and business initiatives across the United States.
Sales & Account ManagementAccount Management
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • Demonstrated successful background in business development, strategic account management, sales, or commercial leadership within healthcare, medical imaging, or a related industry.
  • Strong understanding of the Molecular Imaging and/or outpatient diagnostic imaging market.
  • Ability to build trusted relationships with executive, clinical, and operational stakeholders across complex healthcare organizations.
  • Knowledge of PET/CT, SPECT/CT, Nuclear Medicine, Oncology, Theranostics, Neurology, and/or Cardiology.
  • Ability to develop and execute strategic account plans that translate customer needs and market opportunities into measurable business growth.
  • Strong analytical skills in market intelligence, customer segmentation, pipeline development, and commercial decision-making.
  • Understanding of financial considerations associated with complex commercial offerings, including revenue, profitability, and margin.
  • Ability to communicate and collaborate effectively with customers, senior leadership, field sales teams, and cross-functional stakeholders.
  • Ability to manage multiple complex customer initiatives and priorities across a national geography.
  • Willingness to travel approximately 50% to support strategic customers and business initiatives across the United States.
Responsibilities
  • Develop and execute the Molecular Imaging National Imaging Center strategy across key national and regional outpatient imaging organizations.
  • Accelerate growth through strategic account segmentation, differentiated value propositions, market development initiatives, and measurable business strategies.
  • Partner with Molecular Imaging Business Line leadership and Marketing to develop and execute a comprehensive National Imaging Center business plan.
  • Build relationships with executive decision-makers, clinical leaders, and other key stakeholders within strategic customer organizations.
  • Identify opportunities to expand Molecular Imaging utilization across PET/CT, SPECT/CT, Oncology, Theranostics, Neurology, Cardiology, and emerging clinical applications.
  • Develop customer strategies that align Siemens Healthineers solutions with clinical, operational, and financial priorities.
  • Collaborate with field sales and key account teams on commercial strategies, customer proposals, system configurations, and value-added solutions.
  • Drive market development initiatives associated with emerging Molecular Imaging technologies, radiopharmaceuticals, tracers, and new clinical applications.
  • Monitor customer activity, competitive developments, market trends, and other factors impacting the Molecular Imaging business.
  • Track key business metrics, including market share, revenue, pipeline development, volume, and profitability.
  • Coordinate cross-functional resources across Sales, Marketing, Service, Finance, Operations, and Business Line leadership to support successful customer engagements.
  • Support strategic customers throughout the project lifecycle and serve as a point of contact for escalation and problem resolution.

About the company

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Wellness Program
  • 401(k) Retirement Plan

Growth & Insights and Company News

6 month growth

3%

1 year growth

3%

2 year growth

3%
Varex Imaging Corporation
Sep 14th, 2026
About Us | Varex Imaging Corporation

We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster

MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.